Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Published Online
on March 22, 2004

Hypertension. 2004
Published online before print March 22, 2004, doi: 10.1161/01.HYP.0000126172.01673.84
A more recent version of this article appeared on May 1, 2004
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
43/5/1140    most recent
01.HYP.0000126172.01673.84v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cavasin, M. A.
Right arrow Articles by Carretero, O. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cavasin, M. A.
Right arrow Articles by Carretero, O. A.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*Protein
*UniGene
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*(L)-PROLINE
*CAPTOPRIL
Related Collections
Right arrow Biochemistry and metabolism
Right arrow Remodeling
Right arrow ACE/Angiotension receptors

Submitted on December 1, 2003
Revised on December 30, 2003

Prolyl Oligopeptidase Is Involved in Release of the Antifibrotic Peptide Ac-SDKP

Maria A. Cavasin*; Nour-Eddine Rhaleb; Xiao-Ping Yang; and Oscar A. Carretero

From the Hypertension and Vascular Research Division, Henry Ford Health System, Detroit, Mich.

* To whom correspondence should be addressed. E-mail: mcavasi1{at}hfhs.org.

Abstract--N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) is a ubiquitous tetrapeptide hydrolyzed almost exclusively by angiotensin-converting enzyme (ACE). Chronic treatment with Ac-SDKP decreases cardiac and renal fibrosis and inflammatory cell infiltration in hypertensive rats. However, very little is known about endogenous synthesis of Ac-SDKP, except that thymosin-{beta}4 may be the most likely precursor. Two enzymes are potentially able to release Ac-SDKP from thymosin-{beta}4: prolyl oligopeptidase (POP) and endoproteinase asp-N. POP is widely present and active in several tissues and biological fluids, whereas endoproteinase asp-N appears to be lacking in mammals. Therefore, we hypothesized that POP is the main enzyme involved in synthesizing the antifibrotic peptide Ac-SDKP. We investigated in vitro and in vivo production of Ac-SDKP. Using kidney cortex homogenates, we observed that Ac-SDKP was generated in a time-dependent manner in the presence of exogenous thymosin-{beta}4, and this generation was significantly inhibited by several POP inhibitors (POPi), Z-prolyl-prolinal, Fmoc-prolyl-pyrrolidine-2-nitrile, and S17092. Long-term administration of S17092 in rats significantly decreased endogenous levels of Ac-SDKP in the plasma (from 1.76±0.2 to 1.01±0.1 nM), heart (from 2.31±0.21 to 0.83±0.09 pmol/mg protein), and kidneys (from 5.62±0.34 to 2.86±0.76 pmol/mg protein). As expected, ACE inhibitors significantly increased endogenous levels of Ac-SDKP in the plasma, heart, and kidney, whereas coadministration of POPi prevented this increase. We concluded that POP is the main enzyme responsible for synthesis of the antifibrotic peptide Ac-SDKP.


Key words: angiotensin-converting enzyme • heart • kidney




This article has been cited by other articles:


Home page
J. Bacteriol.Home page
N. C. Ammerman, J. J. Gillespie, A. F. Neuwald, B. W. Sobral, and A. F. Azad
A Typhus Group-Specific Protease Defies Reductive Evolution in Rickettsiae
J. Bacteriol., December 15, 2009; 191(24): 7609 - 7613.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
M. A. Cavasin, T.-D. Liao, X.-P. Yang, J. J. Yang, and O. A. Carretero
Decreased Endogenous Levels of Ac-SDKP Promote Organ Fibrosis
Hypertension, July 1, 2007; 50(1): 130 - 136.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
H. Peng, O. A. Carretero, T.-D. Liao, E. L. Peterson, and N.-E. Rhaleb
Role of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline in the Antifibrotic and Anti-Inflammatory Effects of the Angiotensin-Converting Enzyme Inhibitor Captopril in Hypertension
Hypertension, March 1, 2007; 49(3): 695 - 703.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
M. Paul, A. Poyan Mehr, and R. Kreutz
Physiology of local Renin-Angiotensin systems.
Physiol Rev, July 1, 2006; 86(3): 747 - 803.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
L. Waeckel, J. Bignon, J.-M. Liu, D. Markovits, T. G. Ebrahimian, J. Vilar, B. Mees, O. Blanc-Brude, V. Barateau, S. Le ricousse-Roussanne, et al.
Tetrapeptide AcSDKP Induces Postischemic Neovascularization Through Monocyte Chemoattractant Protein-1 Signaling
Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 773 - 779.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
H. Peng, O. A. Carretero, N. Vuljaj, T.-D. Liao, A. Motivala, E. L. Peterson, and N.-E. Rhaleb
Angiotensin-Converting Enzyme Inhibitors: A New Mechanism of Action
Circulation, October 18, 2005; 112(16): 2436 - 2445.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
D. Wang, O. A. Carretero, X.-Y. Yang, N.-E. Rhaleb, Y.-H. Liu, T.-D. Liao, and X.-P. Yang
N-acetyl-seryl-aspartyl-lysyl-proline stimulates angiogenesis in vitro and in vivo
Am J Physiol Heart Circ Physiol, November 1, 2004; 287(5): H2099 - H2105.
[Abstract] [Full Text] [PDF]